Evidence map›Paper›PMID 41136372›Full record

ArticleCell death discovery2025

TRIM35, a novel DNA-binding protein, epigenetically modifies H3 to promote HSPA6 transcription and suppress breast cancer progression.

Xintao Jing, Fang Li, Jing Zhou, Jinyuan Zhang, Li Cao, Chen Guo, Qian Li, Hang Peng, Qiuyu Jiang, Xiaofei Wang and 5 more

Abstract read
In one paragraph

Article in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xintao JingDepartment of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, Shaanxi, China.ORCID http://orcid.org/0000-0001-9080-4421
Fang LiInstitute of Basic Medical Sciences, Xi'an Medical University, Xi'an, Shaanxi, China.
Jing ZhouDepartment of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Jinyuan ZhangNorthwest Women's and Children's Hospital, Xi'an, Shaanxi, China.
Li CaoDepartment of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Chen GuoDepartment of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Qian LiDepartment of Gastroenterology, The First Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi, China.
Hang PengDepartment of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Qiuyu JiangDepartment of Otolaryngology Head and Neck Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Xiaofei WangBiomedical Experimental Center, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Yanke ChenDepartment of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Jiangbo DingDepartment of Clinical Research, Xianyang Hospital of Yan'an University, Xianyang, China.
Dongdong TongDepartment of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, Shaanxi, China. tongdd@xjtu.edu.cn.ORCID http://orcid.org/0000-0002-2716-5783
Zhenghang ZhaoDepartment of Pharmacology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China. zzh@mail.xjtu.edu.cn.
Chen HuangDepartment of Cell Biology and Genetics, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, Shaanxi, China. hchen@xjtu.edu.cn.ORCID http://orcid.org/0000-0002-0355-3036

Funding

National Natural Science Foundation of China (National Science Foundation of China) 32271006National Natural Science Foundation of China (National Science Foundation of China) 81702918
6 · The paper itself

Abstract

Tripartite Motif Containing 35 (TRIM35) is a well-characterized ubiquitin ligase with established roles in antiviral immunity, cancer metabolism, cardiovascular function, and tumor progression. However, its function as a DNA-binding protein has not been previously explored. In this study, we provide the first evidence that TRIM35 directly binds genomic promoters, thereby identifying it as a novel regulator of gene transcription. This finding opens new avenues for understanding the biological functions of TRIM35, expanding its potential role in cellular regulation. Furthermore, our results show that TRIM35 interacts with histone H3 (H3) and catalyzes its non-proteolytic ubiquitination, which serves as a recruitment signal for p300, leading to subsequent H3K27 acetylation and activation of gene transcription. Notably, among the genes regulated, Heat Shock Protein Family A (Hsp70) Member 6 (HSPA6) is significantly upregulated through TRIM35-mediated transcriptional regulation, which suppresses breast cancer progression and mediates TRIM35's anti-tumor effect. Collectively, our findings reveal a previously unrecognized mechanism by which TRIM35 regulates gene expression through targeted epigenetic modification, providing new insights into its tumor-suppressive role in breast cancer.

Identifiers

PMID41136372
PMCPMC12552751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.